Latest Information Update: 20 May 2003
At a glance
- Originator Sankyo
- Class Antihyperglycaemics; Thiazolidinediones
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 20 May 2003 No development reported - Preclinical for Diabetes mellitus in Japan (unspecified route)
- 15 Feb 2000 Preclinical development for Diabetes mellitus in Japan (Unknown route)